Last reviewed · How we verify

NCT04008446: Vit B12

Effect of Vitamin B12 on the Development of Sepsis, in Culture Positive Patients

Completed Last updated 10 January 2023
What this trial tests

trial in Bacteremia in 100 participants. Completed in 31 December 2022.

Timeline
1 June 2019
Primary endpoint
11 November 2022
31 December 2022

Quick facts

Lead sponsorUniversity of Zurich
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 June 2019
Primary completion11 November 2022
Estimated completion31 December 2022
Sites1 location across Switzerland

Conditions studied

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Bacteremia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an prospective observational study assessing the effect of vitamin B12 on the odds of developing sepsis in patients with infection confirmed by a positive culture result. The hypothesis is that patients with infection confirmed by positive cultures who develop sepsis have lower vitamin B12 levels than patients infection, confirmed by positive cultures, who do not develop sepsis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Vitamin B12 status and the risk of developing sepsis in patients with bacterial infection: a prospective observational cohort study.
    Pregernig A, Held U, Schläpfer M, Beck-Schimmer B. · · 2024 · cited 3× · PMID 39134986 · DOI 10.1186/s12916-024-03552-3

Verify or expand the search:

Other recruiting trials for Bacteremia

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04008446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing